Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Veltassa | patiromer | Hyperkalemia, adults (chronic kidney disease) | Reimburse with clinical criteria and/or conditions | Complete | ||
Velsipity | etrasimod | Ulcerative colitis | Active | |||
Velphoro | sucroferric oxyhydroxide | Hyperphosphatemia, end-stage renal disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Velcade | Bortezomib | Multiple Myeloma | Reimburse | Complete | ||
Veklury | remdesivir | COVID-19 in hospitalized patients | Active | |||
Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
Vectibix | Panitumumab | Left Sided Metastatic Colorectal Cancer (mCRC) | Do not reimburse | Complete | ||
Vectibix | Panitumumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Vascepa | icosapent ethyl | Ischemic events in statin-treated patients | Reimburse with clinical criteria and/or conditions | Complete | ||
Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete |